Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Naporafenib by Erasca for Solid Tumor: Likelihood of Approval
Naporafenib is under clinical development by Erasca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Naporafenib by Erasca for Metastatic Melanoma: Likelihood of Approval
Naporafenib is under clinical development by Erasca and currently in Phase III for Metastatic Melanoma. According to GlobalData, Phase III...
Naporafenib by Erasca for Non-Small Cell Lung Cancer: Likelihood of Approval
Naporafenib is under clinical development by Erasca and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...